Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium experience

John M. Goldberg, Lewis B. Silverman, Donna E. Levy, Virginia Kimball Dalton, Richard D. Gelber, Leslie Lehmann, Harvey J. Cohen, Stephen E. Sallan, Barbara L. Asselin

Research output: Contribution to journalArticle

226 Citations (Scopus)

Abstract

Purpose: T-cell acute lymphoblastic leukemia (T-ALL) accounts for 10% to 15% of newly diagnosed cases of childhood acute lymphoblastic leukemia (ALL). Historically, T-ALL patients have had a worse prognosis than other ALL patients. Patients and Methods: We reviewed the outcomes of 125 patients with T-ALL treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium trials between 1981 and 1995. Therapy included four- or five-agent remission induction; consolidation therapy with doxorubicin, vincristine, corticosteroid, mercaptopurine, and weekly high-dose asparaginase; and cranial radiation. T-ALL patients were treated the same as high-risk B-progenitor ALL patients. Fifteen patients with T-cell lymphoblastic lymphoma were also treated with the same high-risk regimen between 1981 and 2000. Results: The 5-year event-free survival (EFS) rate for T-ALL patients was 75% ± 4%. Fourteen of 15 patients with T-cell lymphoblastic lymphoma were long-term survivors. There was no significant difference in EFS comparing patients with T-ALL and B-progenitor ALL (P = .56), although T-ALL patients had significantly higher rates of induction failure (P < .0001), and central nervous system (CNS) relapse (P = .02). The median time to relapse in T-ALL patients was 1.2 years versus 2.5 years in B-progenitor ALL patients (P = .001). There were no pretreatment characteristics associated with worse prognosis in patients with T-ALL. Conclusion: T-ALL patients fared as well as B-progenitor patients on DFCI ALL Consortium protocols. Patients with T-ALL remain at increased risk for induction failure, early relapse, and isolated CNS relapse. Future studies should focus on the identification of and treatment for T-ALL patients at high risk for treatment failure.

Original languageEnglish
Pages (from-to)3616-3622
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number19
DOIs
StatePublished - Oct 1 2003
Externally publishedYes

Fingerprint

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms
Recurrence
T-Cell Lymphoma
Disease-Free Survival
Biphenotypic Acute Leukemia
Central Nervous System
Remission Induction
Asparaginase
6-Mercaptopurine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Goldberg, J. M., Silverman, L. B., Levy, D. E., Dalton, V. K., Gelber, R. D., Lehmann, L., ... Asselin, B. L. (2003). Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium experience. Journal of Clinical Oncology, 21(19), 3616-3622. https://doi.org/10.1200/JCO.2003.10.116

Childhood T-cell acute lymphoblastic leukemia : The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium experience. / Goldberg, John M.; Silverman, Lewis B.; Levy, Donna E.; Dalton, Virginia Kimball; Gelber, Richard D.; Lehmann, Leslie; Cohen, Harvey J.; Sallan, Stephen E.; Asselin, Barbara L.

In: Journal of Clinical Oncology, Vol. 21, No. 19, 01.10.2003, p. 3616-3622.

Research output: Contribution to journalArticle

Goldberg, JM, Silverman, LB, Levy, DE, Dalton, VK, Gelber, RD, Lehmann, L, Cohen, HJ, Sallan, SE & Asselin, BL 2003, 'Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium experience', Journal of Clinical Oncology, vol. 21, no. 19, pp. 3616-3622. https://doi.org/10.1200/JCO.2003.10.116
Goldberg, John M. ; Silverman, Lewis B. ; Levy, Donna E. ; Dalton, Virginia Kimball ; Gelber, Richard D. ; Lehmann, Leslie ; Cohen, Harvey J. ; Sallan, Stephen E. ; Asselin, Barbara L. / Childhood T-cell acute lymphoblastic leukemia : The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium experience. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 19. pp. 3616-3622.
@article{d2c36507449b41e9bc0146cdcf7a2d78,
title = "Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium experience",
abstract = "Purpose: T-cell acute lymphoblastic leukemia (T-ALL) accounts for 10{\%} to 15{\%} of newly diagnosed cases of childhood acute lymphoblastic leukemia (ALL). Historically, T-ALL patients have had a worse prognosis than other ALL patients. Patients and Methods: We reviewed the outcomes of 125 patients with T-ALL treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium trials between 1981 and 1995. Therapy included four- or five-agent remission induction; consolidation therapy with doxorubicin, vincristine, corticosteroid, mercaptopurine, and weekly high-dose asparaginase; and cranial radiation. T-ALL patients were treated the same as high-risk B-progenitor ALL patients. Fifteen patients with T-cell lymphoblastic lymphoma were also treated with the same high-risk regimen between 1981 and 2000. Results: The 5-year event-free survival (EFS) rate for T-ALL patients was 75{\%} ± 4{\%}. Fourteen of 15 patients with T-cell lymphoblastic lymphoma were long-term survivors. There was no significant difference in EFS comparing patients with T-ALL and B-progenitor ALL (P = .56), although T-ALL patients had significantly higher rates of induction failure (P < .0001), and central nervous system (CNS) relapse (P = .02). The median time to relapse in T-ALL patients was 1.2 years versus 2.5 years in B-progenitor ALL patients (P = .001). There were no pretreatment characteristics associated with worse prognosis in patients with T-ALL. Conclusion: T-ALL patients fared as well as B-progenitor patients on DFCI ALL Consortium protocols. Patients with T-ALL remain at increased risk for induction failure, early relapse, and isolated CNS relapse. Future studies should focus on the identification of and treatment for T-ALL patients at high risk for treatment failure.",
author = "Goldberg, {John M.} and Silverman, {Lewis B.} and Levy, {Donna E.} and Dalton, {Virginia Kimball} and Gelber, {Richard D.} and Leslie Lehmann and Cohen, {Harvey J.} and Sallan, {Stephen E.} and Asselin, {Barbara L.}",
year = "2003",
month = "10",
day = "1",
doi = "10.1200/JCO.2003.10.116",
language = "English",
volume = "21",
pages = "3616--3622",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "19",

}

TY - JOUR

T1 - Childhood T-cell acute lymphoblastic leukemia

T2 - The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium experience

AU - Goldberg, John M.

AU - Silverman, Lewis B.

AU - Levy, Donna E.

AU - Dalton, Virginia Kimball

AU - Gelber, Richard D.

AU - Lehmann, Leslie

AU - Cohen, Harvey J.

AU - Sallan, Stephen E.

AU - Asselin, Barbara L.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Purpose: T-cell acute lymphoblastic leukemia (T-ALL) accounts for 10% to 15% of newly diagnosed cases of childhood acute lymphoblastic leukemia (ALL). Historically, T-ALL patients have had a worse prognosis than other ALL patients. Patients and Methods: We reviewed the outcomes of 125 patients with T-ALL treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium trials between 1981 and 1995. Therapy included four- or five-agent remission induction; consolidation therapy with doxorubicin, vincristine, corticosteroid, mercaptopurine, and weekly high-dose asparaginase; and cranial radiation. T-ALL patients were treated the same as high-risk B-progenitor ALL patients. Fifteen patients with T-cell lymphoblastic lymphoma were also treated with the same high-risk regimen between 1981 and 2000. Results: The 5-year event-free survival (EFS) rate for T-ALL patients was 75% ± 4%. Fourteen of 15 patients with T-cell lymphoblastic lymphoma were long-term survivors. There was no significant difference in EFS comparing patients with T-ALL and B-progenitor ALL (P = .56), although T-ALL patients had significantly higher rates of induction failure (P < .0001), and central nervous system (CNS) relapse (P = .02). The median time to relapse in T-ALL patients was 1.2 years versus 2.5 years in B-progenitor ALL patients (P = .001). There were no pretreatment characteristics associated with worse prognosis in patients with T-ALL. Conclusion: T-ALL patients fared as well as B-progenitor patients on DFCI ALL Consortium protocols. Patients with T-ALL remain at increased risk for induction failure, early relapse, and isolated CNS relapse. Future studies should focus on the identification of and treatment for T-ALL patients at high risk for treatment failure.

AB - Purpose: T-cell acute lymphoblastic leukemia (T-ALL) accounts for 10% to 15% of newly diagnosed cases of childhood acute lymphoblastic leukemia (ALL). Historically, T-ALL patients have had a worse prognosis than other ALL patients. Patients and Methods: We reviewed the outcomes of 125 patients with T-ALL treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium trials between 1981 and 1995. Therapy included four- or five-agent remission induction; consolidation therapy with doxorubicin, vincristine, corticosteroid, mercaptopurine, and weekly high-dose asparaginase; and cranial radiation. T-ALL patients were treated the same as high-risk B-progenitor ALL patients. Fifteen patients with T-cell lymphoblastic lymphoma were also treated with the same high-risk regimen between 1981 and 2000. Results: The 5-year event-free survival (EFS) rate for T-ALL patients was 75% ± 4%. Fourteen of 15 patients with T-cell lymphoblastic lymphoma were long-term survivors. There was no significant difference in EFS comparing patients with T-ALL and B-progenitor ALL (P = .56), although T-ALL patients had significantly higher rates of induction failure (P < .0001), and central nervous system (CNS) relapse (P = .02). The median time to relapse in T-ALL patients was 1.2 years versus 2.5 years in B-progenitor ALL patients (P = .001). There were no pretreatment characteristics associated with worse prognosis in patients with T-ALL. Conclusion: T-ALL patients fared as well as B-progenitor patients on DFCI ALL Consortium protocols. Patients with T-ALL remain at increased risk for induction failure, early relapse, and isolated CNS relapse. Future studies should focus on the identification of and treatment for T-ALL patients at high risk for treatment failure.

UR - http://www.scopus.com/inward/record.url?scp=0142008436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142008436&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.10.116

DO - 10.1200/JCO.2003.10.116

M3 - Article

C2 - 14512392

AN - SCOPUS:0142008436

VL - 21

SP - 3616

EP - 3622

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 19

ER -